INS Share PerformanceMore
|52 week high||328.55 26/09/16|
|52 week low||198.00 25/02/16|
|52 week change||15.00 (7.54%)|
|4 week volume||53,054 27/01/17|
Media for (INS)
Latest News« previous» nextMore
16/01/2017 - 07:50 StockMarketWire
Instem, a leading provider of IT solutions to the global early development healthcare market, says revenues for the year en...
16/01/2017 - 07:13 StockMarketWire
16/01/2017 - 07:00 RNS
Statement regarding a companys trading performance (e.g. profit warning)
09/01/2017 - 14:44 StockMarketWire
Instem, a leading provider of IT solutions to the global early development healthcare market, has appointed MaryBeth Tho...
09/01/2017 - 14:30 RNS
09/01/2017 - 12:01 StockMarketWire
Phil Reason, CEO of Instem (INS) [LSE:INS] the profitable provider of IT applications and technology enabled services to li...
09/01/2017 - 07:00 RNS
RNS Number: 5902T Instem plc 09 January 2017 Instem plc ("Instem" or the "Company") Instem plc to exhibit at Growth & Innovation Forum - Tuesday 31 January , London Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market , announces that the Company will be exhibiting at the Growth & Innovation Forum...
20/12/2016 - 17:23 RNS
RNS Number: 4127S Instem plc 20 December 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Instem PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisition or dispo...
|Dividend yield||0 %|
Equity Research (INS)
Instem has published a short trading update for the year to December 2016. The outcome was in line with (and in some areas slightly ahead of) our expectations. The year was impacted by the slowdown...
Instem recently confirmed that its Instem Clinical business continues to be impacted by a slowdown in the early-phase clinical market and, despite other areas of Instem performing well, that this...
Instem has announced solid interim results. Revenues grew by 21% YoY, accompanied by a 34% improvement in EBITDA. Activity in the pre-clinical segment remains strong, as evidenced by the multi-year...
- 1 of 5
Latest discussion posts More
“"I first spoke to LSE:INS:Instem early last year. The AIM-listed company was worth A#22 million and demand for its software, which helps drug companies develop commercial drugs ...”▼
Codes & Symbols
|Symbols||INS, LSE:INS, INS.L, INS:LN, LON:INS, XLON:INS|